On Sunday, November 17, 2024, Dr. Eric Winer interviewed Francine Foss, MD, Professor of Medicine (Hematology) and of Dermatology. Dr. Foss is an internationally recognized clinician and clinical researcher with expertise in adult lymphomas and in stem cell transplantation.
On this episode of Yale Cancer Answers, Dr. Foss discusses the recent approval of a new drug to treat a rare type of lymphoma. Known as Lymphir, the novel immunotherapy was recently FDA approved for the treatment of relapsed or refractory cutaneous T-cell lymphoma (CTCL), a rare from of non-Hodgkin lymphoma.
“As a physician who treats patients with cutaneous lymphoma, I was thrilled to hear that the FDA approved Lymphir, which is a highly active drug, and a new option for patients with persistent or relapsed disease,” said Dr. Foss.